VEA
CCCC icon

Virtus ETF Advisers’s C4 Therapeutics CCCC Stock Holding History

Virtus ETF Advisers’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,350
Closed -$38.8K – 443
2023
Q1 		$38.8K Sell
12,350
-4,752
-28% -$28K 0.02% 438
2022
Q4 		$101K Sell
17,102
-2,203
-11% -$18.3K 0.05% 439
2022
Q3 		$169K Buy
19,305
+136
+0.7% +$1.41K 0.07% 334
2022
Q2 		$145K Buy
19,169
+13,894
+263% +$122K 0.05% 322
2022
Q1 		$128K Sell
5,275
-314
-6% -$7.63K 0.06% 251
2021
Q4 		$180K Buy
5,589
+546
+11% +$21.6K 0.07% 246
2021
Q3 		$225K Sell
5,043
-269
-5% -$11.5K 0.1% 239
2021
Q2 		$201K Buy
+5,312
New +$190K 0.08% 341

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Virtus ETF Advisers's CCCC Position: Q2 2023 in Review

Virtus ETF Advisers sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 12,350 shares — an estimated $38.8K sold.

Virtus ETF Advisers first reported a position in CCCC in Q2 2021 and held it in 8 quarters. The position peaked at $225K in Q3 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Virtus ETF Advisers reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 12,350 C4 Therapeutics shares in Q2 2023, an estimated $38.8K.
  • Virtus ETF Advisers first reported a position in C4 Therapeutics in Q2 2021 and held it in 8 quarters.
  • Virtus ETF Advisers's C4 Therapeutics position peaked at $225K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.